Literature DB >> 21199867

Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1.

Zhonghui Lin1, Longguang Jiang, Cai Yuan, Jan K Jensen, Xu Zhang, Zhipu Luo, Barbara C Furie, Bruce Furie, Peter A Andreasen, Mingdong Huang.   

Abstract

Plasminogen activator inhibitor-1 (PAI-1), together with its physiological target urokinase-type plasminogen activator (uPA), plays a pivotal role in fibrinolysis, cell migration, and tissue remodeling and is currently recognized as being among the most extensively validated biological prognostic factors in several cancer types. PAI-1 specifically and rapidly inhibits uPA and tissue-type PA (tPA). Despite extensive structural/functional studies on these two reactions, the underlying structural mechanism has remained unknown due to the technical difficulties of obtaining the relevant structures. Here, we report a strategy to generate a PAI-1·uPA(S195A) Michaelis complex and present its crystal structure at 2.3-Å resolution. In this structure, the PAI-1 reactive center loop serves as a bait to attract uPA onto the top of the PAI-1 molecule. The P4-P3' residues of the reactive center loop interact extensively with the uPA catalytic site, accounting for about two-thirds of the total contact area. Besides the active site, almost all uPA exosite loops, including the 37-, 60-, 97-, 147-, and 217-loops, are involved in the interaction with PAI-1. The uPA 37-loop makes an extensive interaction with PAI-1 β-sheet B, and the 147-loop directly contacts PAI-1 β-sheet C. Both loops are important for initial Michaelis complex formation. This study lays down a foundation for understanding the specificity of PAI-1 for uPA and tPA and provides a structural basis for further functional studies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21199867      PMCID: PMC3044959          DOI: 10.1074/jbc.M110.204537

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

1.  A regulatory hydrophobic area in the flexible joint region of plasminogen activator inhibitor-1, defined with fluorescent activity-neutralizing ligands. Ligand-induced serpin polymerization.

Authors:  R Egelund; A P Einholm; K E Pedersen; R W Nielsen; A Christensen; J Deinum; P A Andreasen
Journal:  J Biol Chem       Date:  2001-01-25       Impact factor: 5.157

2.  High-resolution structure of the stable plasminogen activator inhibitor type-1 variant 14-1B in its proteinase-cleaved form: a new tool for detailed interaction studies and modeling.

Authors:  Jan K Jensen; Peter G W Gettins
Journal:  Protein Sci       Date:  2008-08-25       Impact factor: 6.725

3.  Conversion of the active to latent plasminogen activator inhibitor from human endothelial cells.

Authors:  E G Levin; L Santell
Journal:  Blood       Date:  1987-10       Impact factor: 22.113

4.  Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.

Authors:  L S Gutierrez; A Schulman; T Brito-Robinson; F Noria; V A Ploplis; F J Castellino
Journal:  Cancer Res       Date:  2000-10-15       Impact factor: 12.701

Review 5.  The plasminogen activation system in tumor growth, invasion, and metastasis.

Authors:  P A Andreasen; R Egelund; H H Petersen
Journal:  Cell Mol Life Sci       Date:  2000-01-20       Impact factor: 9.261

6.  High quality structure of cleaved PAI-1-stab.

Authors:  M Dewilde; S V Strelkov; A Rabijns; P J Declerck
Journal:  J Struct Biol       Date:  2008-11-27       Impact factor: 2.867

7.  Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1.

Authors:  K Aertgeerts; H L De Bondt; C J De Ranter; P J Declerck
Journal:  Nat Struct Biol       Date:  1995-10

Review 8.  The urokinase plasminogen activator system: a target for anti-cancer therapy.

Authors:  Salvatore Ulisse; Enke Baldini; Salvatore Sorrenti; Massimino D'Armiento
Journal:  Curr Cancer Drug Targets       Date:  2009-02       Impact factor: 3.428

9.  The acid stabilization of plasminogen activator inhibitor-1 depends on protonation of a single group that affects loop insertion into beta-sheet A.

Authors:  J O Kvassman; D A Lawrence; J D Shore
Journal:  J Biol Chem       Date:  1995-11-17       Impact factor: 5.157

10.  Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin.

Authors:  Wei Li; Daniel J D Johnson; Charles T Esmon; James A Huntington
Journal:  Nat Struct Mol Biol       Date:  2004-08-15       Impact factor: 15.369

View more
  28 in total

1.  Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies.

Authors:  Kenneth A Botkjaer; Sarah Fogh; Erin C Bekes; Zhuo Chen; Grant E Blouse; Janni M Jensen; Kim K Mortensen; Mingdong Huang; Elena Deryugina; James P Quigley; Paul J Declerck; Peter A Andreasen
Journal:  Biochem J       Date:  2011-08-15       Impact factor: 3.857

2.  Urokinase-type plasminogen activator-like proteases in teleosts lack genuine receptor-binding epidermal growth factor-like domains.

Authors:  René Bager; Thomas K Kristensen; Jan K Jensen; Agnieszka Szczur; Anni Christensen; Lisbeth M Andersen; Jesper S Johansen; Niels Larsen; Erik Baatrup; Mingdong Huang; Michael Ploug; Peter A Andreasen
Journal:  J Biol Chem       Date:  2012-06-25       Impact factor: 5.157

3.  Inhibition of PAI-1 antiproteolytic activity against tPA by RNA aptamers.

Authors:  Jared Damare; Stephanie Brandal; Yolanda M Fortenberry
Journal:  Nucleic Acid Ther       Date:  2014-06-12       Impact factor: 5.486

4.  Biochemical and structural analyses suggest that plasminogen activators coevolved with their cognate protein substrates and inhibitors.

Authors:  Agnieszka Jendroszek; Jeppe B Madsen; Andrés Chana-Muñoz; Daniel M Dupont; Anni Christensen; Frank Panitz; Ernst-Martin Füchtbauer; Simon C Lovell; Jan K Jensen
Journal:  J Biol Chem       Date:  2019-01-16       Impact factor: 5.157

5.  Contribution of conserved lysine residues in the alpha2-antiplasmin C terminus to plasmin binding and inhibition.

Authors:  Bernadine G C Lu; Trifina Sofian; Ruby H P Law; Paul B Coughlin; Anita J Horvath
Journal:  J Biol Chem       Date:  2011-05-04       Impact factor: 5.157

6.  Targeting plasminogen activator inhibitor-1 in tetracycline-induced pleural injury in rabbits.

Authors:  Galina Florova; Ali O Azghani; Sophia Karandashova; Chris Schaefer; Serge V Yarovoi; Paul J Declerck; Douglas B Cines; Steven Idell; Andrey A Komissarov
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-31       Impact factor: 5.464

7.  Characterization of a small molecule inhibitor of plasminogen activator inhibitor type 1 that accelerates the transition into the latent conformation.

Authors:  Ola Fjellström; Johanna Deinum; Tove Sjögren; Carina Johansson; Stefan Geschwindner; Viveca Nerme; Anne Legnehed; Jane McPheat; Karolina Olsson; Cristian Bodin; Amalia Paunovic; David Gustafsson
Journal:  J Biol Chem       Date:  2012-11-15       Impact factor: 5.157

8.  Crystal Structure of the Michaelis Complex between Tissue-type Plasminogen Activator and Plasminogen Activators Inhibitor-1.

Authors:  Lihu Gong; Min Liu; Tu Zeng; Xiaoli Shi; Cai Yuan; Peter A Andreasen; Mingdong Huang
Journal:  J Biol Chem       Date:  2015-08-31       Impact factor: 5.157

9.  Remarkable stabilization of plasminogen activator inhibitor 1 in a "molecular sandwich" complex.

Authors:  Galina Florova; Sophia Karandashova; Paul J Declerck; Steven Idell; Andrey A Komissarov
Journal:  Biochemistry       Date:  2013-06-25       Impact factor: 3.162

10.  Single fluorescence probes along the reactive center loop reveal site-specific changes during the latency transition of PAI-1.

Authors:  Tihami Qureshi; Cynthia B Peterson
Journal:  Protein Sci       Date:  2015-11-25       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.